AbbVie (ABBV) closed the most recent trading day at $153.93, moving +0.08% from the previous trading session.
The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be its fifth indication in that market. This would be to treat patients with moderate-to-severe ulcerative colitis who had an inadequate response to conventional therapies or biologic agents. A decision for Rinvoq as a treatment for moderate-to-severe ulcerative colitis patients from the European Commission is expected in the third quarter of this year.
Three little words can make you a lot of money over the long term: Buy and hold. Here's why they picked AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Vertex Pharmaceuticals (NASDAQ: VRTX). Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie is currently defying gravity.